United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, llc - fluoxymesterone (unii: 9ju12s4yfy) (fluoxymesterone - unii:9ju12s4yfy) - fluoxymesterone 10 mg - androxy™ tablets are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. idiopathic gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) if the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. androxy™ (fluoxymesterone tablets, usp) may be used to stimulate puberty in carefully selected males with clearly delayed puberty. these patient

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company - fluoxymesterone (unii: 9ju12s4yfy) (fluoxymesterone - unii:9ju12s4yfy) - tablet - 2 mg - in the male —halotestin tablets are indicated for - replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. - primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. - delayed puberty, provided it has been definitely established as such, and is not just a familial trait. in the female —halotestin tablets are indicated for palliation of androgen-responsive recurr

Canada - English - Health Canada

pfizer canada ulc - fluoxymesterone - tablet - 5mg - fluoxymesterone 5mg - androgens

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - fluoxymesterone 5mg - tablet - 5 mg - active: fluoxymesterone 5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

ciba geigy plc - fluoxymesterone - tablets - 5 milligram

United States - English - NLM (National Library of Medicine)

creekwood pharmaceutical, inc, - methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif), estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 1.25 mg - esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women with any of the following conditions: - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - known or suspected pregnancy (see boxed warning). - undiagnose

United States - English - NLM (National Library of Medicine)

centrix pharmaceutical, inc, - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 1.25 mg - covaryxt® and covaryx® h.s. are indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) covaryxt® and covaryx® h.s. have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warnings). estrogens should not be used in women with any of the following conditions: - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - known or suspected pregnancy (see boxed warnings). - undiagnosed abnormal genital bleeding. - active thrombophlebitis or thromboembolic disorders. - a past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previ

United States - English - NLM (National Library of Medicine)

tal pharma llc - estrone sodium sulfate (unii: 6k6fda543a) (estrone - unii:2di9ha706a), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrone sodium sulfate 1.25 mg - esterified estrogens and methyltestosterone tablets full strength and half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone tablets full strength and half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning ). estrogens should not be used in women with any of the following conditions: - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - known or suspected pregnancy (see boxed warning ). - undiagnosed abnormal genital bleeding. - active thrombophlebitis or thromboemb

United States - English - NLM (National Library of Medicine)

method pharmaceuticals, llc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 0.625 mg - esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women with any of the following conditions: 1.       known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2.       known or suspected estrogen-dependent ne

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg